Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazolin-7-yl)oxy]butyramide (RS-82856)
作者:Michael C. Venuti、Gordon H. Jones、Robert Alvarez、John J. Bruno
DOI:10.1021/jm00385a012
日期:1987.2
steric bulk of substituents on the 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one heterocycle and the position and length of the side chain. As inhibitors of cyclic AMP phosphodiesterase (PDE), potency steadily increased with increasingly lipophilic side chains. In platelet aggregation inhibition studies, however, a maximum in activity was reached with 1, while more lipophilic compounds were significantly
环状AMP磷酸二酯酶(PDE)抑制剂N-环己基-N-甲基-4-[(1,2,3,5-四氢-2-氧代咪唑并[2,1-b]喹唑啉-7-基的一系列类似物)氧基]丁酰胺(RS-82856,1)是通过侧链取代基,长度,位置,连接原子和母体杂环本身的系统变化而制备的。将该化合物评价为人血小板和大鼠或狗心脏组织中环状AMP磷酸二酯酶的抑制剂,以及作为ADP诱导的血小板聚集的抑制剂。类似物系列的结构活性相关性表明,对1,2,3,5-四氢咪唑并[2,1-b]喹唑啉-2-一杂环的取代基的空间体积以及侧链的位置和长度有明显的限制。作为环状AMP磷酸二酯酶(PDE)的抑制剂,随着亲脂性侧链的增加,效力逐渐增加。但是,在血小板凝集抑制研究中,活性达到1的最大值,而更多的亲脂性化合物的活性明显降低。杂环本身的主要变化(以异构体和其他羰基变化表示)也降低了活性。由一系列类似物1定义的分子特征与当前对环状AMP PDE的F